Announcement PDF Results of Annual General Meeting 27 November 2024 LTR Pharma Limited (ASX:LTP) (“LTR Pharma”, “the Company”), is pleased to advise that at the Annual General Meeting held today at 2.00pm (AEST), shareholders of the Company passed all Resolutions as set out in the Notice of Meeting dated 28 October 2024 by way of poll. In accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act a summary of the proxy votes received and poll results on each Resolution is attached. – ENDS – This announcement has been approved by the Company Secretary. About LTR Pharma LTR Pharma is focused on improving men’s health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships across multiple age brackets. LTR Pharma’s lead product, SPONTAN®, is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body, supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences. For further information, please contact: Haley Chartres Media Relations haley@hck.digital Peter McLennan Investor Relations investors@ltrpharma.com Disclosure of Proxy Votes Automic GPO Box 5193, Sydney, NSW 2001 P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world) F +61 (0)2 8583 3040 E hello@automic.com.au ABN 27 152 260 814 LTR Pharma Limited Annual General Meeting Wednesday, 27 November 2024 In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting. Poll Results (if applicable) Proxy Votes Resolution Decided by Show of Hands (S) or Poll (P) Total Number of Proxy Votes exercisable by proxies validly appointed 1 Adoption of Remuneration Report P 2,402,818 2 Re-election of Julian Chick as Director P 55,221,844 3 Ratification of Prior Issue of Fully Paid Ordinary Shares P 55,179,844 4 ASX Listing Rule 7.1A Approval of Future Issue of Securities P 55,299,844 5 Approval of Issue of Options to Lee Rodne, Director of the Company P 2,631,306 6 Approval of Issue of Options to Julian Chick, Director of the Company P 55,304,840 7 Approval of Issue of Options to Maja McGuire, Director of the Company P 55,069,348 FOR AGAINST 2,190,516 129,460 91.16% 5.39% 55,129,002 10,000 99.83% 0.02% 54,941,307 155,695 99.57% 0.28% 54,313,947 903,055 98.22% 1.63% 1,957,004 541,460 74.37% 20.58% 54,630,538 541,460 98.78% 0.98% 54,395,046 541,460 98.78% 0.98% PROXY'S DISCRETION ABSTAIN 0 90,000 132,000 12,000 2,118,788 7,004 7,004 FOR AGAINST 82,842 8,650,425 129,460 3.45% 98.53% 1.47% 82,842 61,588,911 10,000 0.15% 99.98% 0.02% 82,842 61,401,216 155,695 0.15% 99.75% 0.25% 82,842 60,773,856 903,055 0.15% 98.54% 1.46% 132,842 8,466,913 541,460 5.05% 93.99% 6.01% 132,842 61,140,447 541,460 0.24% 99.12% 0.88% 132,842 60,904,955 541,460 0.24% 99.12% 0.88% Results ABSTAIN OUTCOME 0 - 90,000 Carried 132,000 Carried 12,000 Carried 2,118,788 Carried 7,004 Carried 7,004 Carried